The impact of angiotensin II receptor blocker potency on the clinical outcomes of stroke, acute myocardial infarction, or death

Formulary

Volumn 42, Issue 10, 2007, Pages

  Baker, William L ^a,b   White, C Michael ^a,b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG POTENCY; FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; INCIDENCE; MEDICAL LITERATURE; MEDICAL RESEARCH; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 35648993481     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Pfeffer MA, Swedberg K, Granger CB; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet. 2003;362:759-766.
2. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
3. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus Captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
4. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction [erratum in Ann Intern Med. 2005;42:391]. Ann Intern Med. 2004;141:693-704.
5. Pfeffer MA, McMurray JJV, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [erratum in N Engl J Med. 2004;350:203]. N Engl J Med. 2003;349:1893-1906.
6. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
8. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
9. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
10. Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
11. Lithell H, Hansson L, Skoog I, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
12. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
13. Maggioni AP. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther. 2006;20:295-308.
14. 1-receptor blockers. J Hum Hypertens. 1999;13(suppl 1):S11-S20.
15. Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000;20:130-139.
16. 1-receptor blockers in isolated vessels of different origin. Hypertension. 1999;33:1406-1413.
17. 1-receptor antagonists in the isolated rabbit thoracic aorta. J Hypertens. 2002;20:1821-1828.
18. Verheijen I, Fierens FL, Debacker JP, Vauquelin G, Vanderheyden PM. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam Clin Pharmacol. 2000;14:577-585.
19. 2 on human saphenous veins. J Cardiovasc Pharmacol. 2003;42:42-47.
20. Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther. 1999;66:367-373.
21. 1 receptor antagonists. Hypertension. 1999;33:850-855.
22. Maillard MP, Wurzner G, Nussberger J, Centeno C, Bernier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther. 2002;71:68-76.
23. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators [erratum in Am J Hypertens. 1998;11:736]. Am J Hypertens. 1998;11:445-453.
24. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27:457-464.
25. 1-receptor blockers. Differences in potency and efficacy. Blood Press. 2002;11:293-301.
26. 1 receptors. Br J Pharmacol. 1999;126:1057-1065.
27. 1 receptor antagonists: The role of tight antagonist binding. Eur J Pharmacol. 1999;372:199-206.
28. Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract. 2006;60:391-398.
29. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan [erratum in Am J Cardiovasc Drugs. 2005;5:209]. Am J Cardiovasc Drugs. 2005;5:41-50.
30. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit. 2002;7;135-142.
31. Goldstein LB, Adams R, Alberts MJ, et al; American Heart Association/American Stroke Association Stroke Council: Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline [erratum in Stroke. 2007;38:207]. Stroke. 2006;37:1583-1633.
32. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
33. Antman EM, Anbe DT, Armstrong PW, et al; American College of Cardiology; American Heart Association; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines on the management of patients with acute myocardial infarction) [erratum in J Am Coll Cardiol. 2005;45:1376]. J Am Coll Cardiol. 2004;44:671-719.
34. Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl. 2006;24:S115-S121.
35. Papadopoulos DP, Papademetriou V. Targeting angiotensin II type 1 receptors to reduce the risk of stroke in patients with hypertension. Expert Opin Ther Targets. 2006;10:231-237.
36. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
38. Schrader J, Luders S, Kulschewski A, et al; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226.
39. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-617.
40. Schrader J, Luders S, Kulschewski A, et al; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34:1699-1703.
41. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet. 2003;362:777-781.
42. Granger CB, McMurray JJ, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362:772-776.
43. Kondo J, Sone T, Tsuboi H, et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J. 2003;146:E20.
44. Haneda M, Kikkawa R, Sakai H, Kawamori R; Candesartan in Diabetic Nephropathy Study. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract. 2004;66:87-95.
45. Suzuki H, Kanno Y; Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients [erratum in Hypertens Res. 2005;28:553]. Hypertens Res. 2005;28:307-314.
46. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: Deeds and misdeeds. J Hypertens. 2005;23:2113-2118.
47. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J. 2005;26:2381-2386.
48. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: Systematic review. BMJ. 2005;331:873-878.
49. 2 receptor - a matter of love and hate. Peptides. 2005;26:1401-1409.
50. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329:1248-1249.
51. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation. 2004;109:8-13.